NCT07330674招募中1 期
A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Number of Participants with treatment-emergent adverse event
研究概览
简要总结
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
详细描述
Part A will be a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy participants.
Part B will be a randomized, double-blind, placebo-controlled, multiple ascending doses (MAD) study in healthy participants.
Part C will be an open-label study in participants with AMD. For Part A and B, serial blood samples will be collected to assess the PK of ABF-101. Ocular examinations will be conducted to evaluate changes in ocular characteristics and function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Part A and B
- •Healthy participants, aged between 18 and 50 years
- •Provides written, signed, informed consent prior to selection
- •BMI of ≥ 18.0 and < 32.0 kg/m2, and body weight between 50 kg and 115 kg, inclusive.
- •Vital signs: normal pulse rate and blood pressure.
- •Must be willing to abstain from caffeine and alcohol
- •Must be willing to avoid strenuous activity
- •Confirmed diagnosis of AMD
- •Male or female ≥50 years of age
- •Adequate visual acuity in the non-study eye
排除标准
- •Part A and B
- •Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease
- •Any significant abnormalities detected during ocular examination,
- •Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician
- •Any drug intake (except paracetamol or contraceptives)
- •History or presence alcohol abuse
- •History or presence of drug abuse
- •Positive HBsAg or anti-HCV antibody, or positive results for HIV
- •Blood donation, significant blood loss, or has received a transfusion of any blood or blood products
- •Female participants who are breastfeeding.
- •Female participants must not be pregnant or at risk to become pregnant during the study. Male and female participants must agree to use highly effective contraception
- •Participant who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language barrier or poor mental development
- •Evidence of CNV due to any cause other than AMD
- •History of vitreoretinal surgery
- •Significant ocular diseases that may interfere with the study
- •Significantly impaired renal or hepatic function
- •Use of immunosuppressive drugs
- •Use of any investigational agent or participation in any other clinical trial of an investigational agent or investigational therapy
- •History of severe drug allergies or drug hypersensitivity syndrome
- •Undiagnosed acute illness first observed during screening or between screening and baseline, or severe concurrent medical conditions that, in the investigator's judgment, represent a safety concern.
- •Severe cardiac disease.
- •QTc ≥450 msec or participants with a history of risk factors or other clinically significant ECG abnormalities
- •Stroke or transient ischemic attack
- •Any major surgical procedure w
- •Serious active infection, other serious medical condition or any other condition that would impair the ability of the participant to administer the investigational drug or to adhere to the study protocol requirements
- •Presence of any condition which, in the judgment of the investigator, would prevent the participant from completing the study
研究组 & 干预措施
Part A (ABF-101 or Placebo)
Experimental
- Part A (Phase 1a) will be a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy participants.
- Capsule, single oral dose
干预措施: ABF-101 (Drug)
Part A (ABF-101 or Placebo)
Experimental
- Part A (Phase 1a) will be a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy participants.
- Capsule, single oral dose
干预措施: Placebo (Drug)
Part B (ABF-101 or Placebo)
Experimental
- Part B (Phase 1b) will be a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study in healthy participants.
- Capsule, once daily by mouth
干预措施: ABF-101 (Drug)
Part B (ABF-101 or Placebo)
Experimental
- Part B (Phase 1b) will be a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study in healthy participants.
- Capsule, once daily by mouth
干预措施: Placebo (Drug)
Part C (ABF-101)
Experimental
- Part C will be an open-label study in participants with AMD
- Capsule, once daily by mouth
干预措施: ABF-101 (Drug)
结局指标
主要结局
Number of Participants with treatment-emergent adverse event
时间窗: From enrollment up to 12 weeks
To investigate the safety and tolerability of single ascending dose of ABF-101orally administered in healthy participants (Part A and B) and in AMD (Part C)
次要结局
- Terminal elimination half-life of ABF-101(From enrollment up to 12 weeks)
- Maximum Observed Plasma Concentration (Cmax) of ABF-101(From enrollment up to 12 weeks)
- The plasma area under the curve (AUC) of ABF-101(From enrollment up to 12 weeks)
- Time to maximal concentration (Tmax) of ABF-101(From enrollment up to 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 12024-518144-20-00Arbor Biotechnologies Inc.6
已完成
2 期
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid TumorsRenal Cell CarcinomaNon-Small Cell Lung Cancer2022-500694-14-00Beigene Ltd., Beigene Ltd.48
招募中
2 期
Study to test the safety and how well patients with severe hemophilia A respond to treatment with BAY 2599023 (DTX 201), a drug therapy that delivers a healthy version of the defective Factor VIII gene into the nucleus of liver cells using an altered, non-infectious virus (AAV) as a "shuttle".Hemophilia A2023-505827-29-00Bayer AG, Bayer AG6
招募中
1 期
A Study of MHB009C in Patients With Advanced Solid TumorsNCT07326488Minghui Pharmaceutical (Hangzhou) Ltd200
尚未招募
不适用
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.NCT07266324Bright Minds Biosciences Pty Ltd16